Table 1 Cell-free mRNA in DLBCL
From: Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
References | Method | Sample | mRNA | Level | Result |
|---|---|---|---|---|---|
Diagnosis | |||||
Garcia et al. [41] | RT-qPCR plasma | 42 DLBCL 50 controls | CCND2, BCL2, MYC, LMO2 BCL6, FN1 | Up NS | Higher level in DLBCL No difference |
Zhao et al.[44] | RT-qPCR peripheral blood | 63 DLBCL 32 controls | CREBBP | Up | Higher level in DLBCL |
Response to therapy | |||||
Garcia et al. [41] | RT-qPCR plasma | 42 DLBCL 50 controls | MYC CCND2, BCL2, LMO2, BCL6,FN1 | Up NS | Higher level of MYC was associated with PR in patients with low-risk IPI No significant association with response to R-CHOP |
Attia et al. [45] | RT-qPCR plasma | 30 NHL (15 DLBCL) 20 controls | SOCS-3 | Up | Higher level was associated with poor response to treatment (NR/PR versus CR) in NHL |
Prognosis | |||||
Garcia et al. [41] | RT-qPCR plasma | 42 DLBCL 50 controls | MYC, CCND2 CCND2, BCL2, MYC | Up Up | Higher level of MYC or CCND2 was associated with worse OS, with the latter only in low-risk IPI group Higher level of CCND2, BCL2 or MYC in patients with CR was associated with worse PFS |
Ujj et al. [47] | RT-qPCR PAXgene blood RNA tube | 25 DLBCL 35 controls | WT1 | Up | Higher level in pre-, intra- or posttreatment samples was associated with worse DFS and OS |